Comparative Pharmacology
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus TAZIDIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANIXINE DISPERDOSE versus TAZIDIME IN PLASTIC CONTAINER.
PANIXINE DISPERDOSE vs TAZIDIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-3, leading to cell lysis and death. It is a beta-lactam antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
1-2 g intravenously every 8 hours for most infections; up to 2 g every 6 hours for severe infections, particularly in neutropenic patients or those with cystic fibrosis.
None Documented
None Documented
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Terminal elimination half-life 1.7-2.0 hours in adults with normal renal function; prolonged to 12-30 hours in end-stage renal disease.
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic